Key challenges to the development of extracorporeal bioartificial liver support systems

Hepatobiliary and Pancreatic Diseases International

Volumn 11, Issue 3, 2012, Pages 243-249

  Zhao, Li Fu ^a   Pan, Xiao Ping ^a   Li, Lan Juan ^a  

^a ZHEJIANG UNIVERSITY   (China)

Author keywords

Bioartificial liver; Bioreactor; Cell source; Liver failure

Indexed keywords

CARBON DIOXIDE; FLUOROCARBON; GLUTAMATE AMMONIA LIGASE; HEMOGLOBIN;

ALBUMIN DIALYSIS; BILE SECRETION; BIOARTIFICIAL LIVER; BIOREACTOR; BLOOD CLOTTING; BLOOD OXYGEN TENSION; BODY TEMPERATURE; CARCINOGENESIS; CELL DIFFERENTIATION; CELL VIABILITY; DISEASE TRANSMISSION; EMERGENCY CARE; ENDOTHELIUM CELL; FREEZE THAWING; HEART INFARCTION; HEMOLYSIS; HUMAN; IMMUNOGENICITY; IN VITRO STUDY; IN VIVO STUDY; KUPFFER CELL; LIVER CELL; LIVER FAILURE; LIVER STRUCTURE; LIVER TUMOR; MEDLINE; NONHUMAN; OXYGEN SUPPLY; OXYGENATION; PH; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PLASMAPHERESIS; REVIEW; STELLATE CELL; SYSTEMATIC REVIEW; TUMOR CELL LINE; ZOONOSIS;

EID: 84861971334     PISSN: 14993872     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1499-3872(12)60155-6     Document Type: Review

References (71)

1. Kjaergard LL, Liu J, Als-Nielsen B, Gluud C. Artificial and bioartificial support systems for acute and acute-on-chronic liver failure: a systematic review. JAMA 2003;289:217-222.
2. Polson J, Lee WM; American Association for the Study of Liver Disease. AASLD position paper: the management of acute liver failure. Hepatology 2005;41:1179-1197.
3. Du WB, Li LJ, Huang JR, Yang Q, Liu XL, Li J, et al. Effects of artificial liver support system on patients with acute or chronic liver failure. Transplant Proc 2005;37:4359-4364.
4. Mas A, Rodés J. Fulminant hepatic failure. Lancet 1997;349: 1081-1085.
5. Strain AJ, Neuberger JM. A bioartificial liver--state of the art. Science 2002;295:1005-1009.
6. Carpentier B, Gautier A, Legallais C. Artificial and bioartificial liver devices: present and future. Gut 2009;58:1690-1702.
7. Pless G. Artificial and bioartificial liver support. Organogenesis 2007;3:20-24.
8. McKenzie TJ, Lillegard JB, Nyberg SL. Artificial and bioartificial liver support. Semin Liver Dis 2008;28:210-217.
9. Sechser A, Osorio J, Freise C, Osorio RW. Artificial liver support devices for fulminant liver failure. Clin Liver Dis 2001;5:415-430.
10. van de Kerkhove MP, Hoekstra R, Chamuleau RA, van Gulik TM. Clinical application of bioartificial liver support systems. Ann Surg 2004;240:216-230.
11. Adham M. Extracorporeal liver support: waiting for the deciding vote. ASAIO J 2003;49:621-632.
12. Demetriou AA. Hepatic assist devices. Panminerva Med 2005;47:31-37.
13. Santoro A, Mancini E, Ferramosca E, Faenza S. Liver support systems. Contrib Nephrol 2007;156:396-404.
14. Rozga J. Liver support technology--an update. Xenotransplantation 2006;13:380-389.
15. Chamuleau RA. Future of bioartificial liver support. World J Gastrointest Surg 2009;1:21-25.
16. Sussman NL, Kelly JH. Improved liver function following treatment with an extracorporeal liver assist device. Artif Organs 1993;17:27-30.
17. Millis JM, Cronin DC, Johnson R, Conjeevaram H, Conlin C, Trevino S, et al. Initial experience with the modified extracorporeal liver-assist device for patients with fulminant hepatic failure: system modifications and clinical impact. Transplantation 2002;74:1735-1746.
18. Ellis AJ, Hughes RD, Wendon JA, Dunne J, Langley PG, Kelly JH, et al. Pilot-controlled trial of the extracorporeal liver assist device in acute liver failure. Hepatology 1996;24:1446-1451.
19. Sussman NL, Gislason GT, Conlin CA, Kelly JH. The Hepatix extracorporeal liver assist device: initial clinical experience. Artif Organs 1994;18:390-396.
20. Millis JM, Cronin DC, Johnson R, Conjeevaram H, Faust TW, Trevino S, et al. Bioartificial liver support: report of the longest continuous treatment with human hepatocytes. Transplant Proc 2001;33:1935.
21. Pitkin Z, Mullon C. Evidence of absence of porcine endogenous retrovirus (PERV) infection in patients treated with a bioartificial liver support system. Artif Organs 1999; 23:829-833.
22. Samuel D, Ichai P, Feray C, Saliba F, Azoulay D, Arulnaden JL, et al. Neurological improvement during bioartificial liver sessions in patients with acute liver failure awaiting transplantation. Transplantation 2002;73:257-264.
23. Demetriou AA, Whiting J, Levenson SM, Chowdhury NR, Schechner R, Michalski S, et al. New method of hepatocyte transplantation and extracorporeal liver support. Ann Surg 1986;204:259-271.
24. Demetriou AA, Brown RS Jr, Busuttil RW, Fair J, McGuire BM, Rosenthal P, et al. Prospective, randomized, multicenter, controlled trial of a bioartificial liver in treating acute liver failure. Ann Surg 2004;239:660-667.
25. Mullon C, Pitkin Z. The HepatAssist bioartificial liver support system: clinical study and pig hepatocyte process. Expert Opin Investig Drugs 1999;8:229-235.
26. Demetriou AA, Rozga J, Podesta L, Lepage E, Morsiani E, Moscioni AD, et al. Early clinical experience with a hybrid bioartificial liver. Scand J Gastroenterol Suppl 1995;208:111-117.
27. Mazariegos GV, Patzer JF 2nd, Lopez RC, Giraldo M, Devera ME, Grogan TA, et al. First clinical use of a novel bioartificial liver support system (BLSS). Am J Transplant 2002;2:260-266.
28. Patzer JF 2nd, Mazariegos GV, Lopez R, Molmenti E, Gerber D, Riddervold F, et al. Novel bioartificial liver support system: preclinical evaluation. Ann N Y Acad Sci 1999;875:340-352.
29. Mazariegos GV, Kramer DJ, Lopez RC, Shakil AO, Rosenbloom AJ, DeVera M, et al. Safety observations in phase I clinical evaluation of the Excorp Medical Bioartificial Liver Support System after the first four patients. ASAIO J 2001;47: 471-475.
30. van de Kerkhove MP, Di Florio E, Scuderi V, Mancini A, Belli A, Bracco A, et al. Bridging a patient with acute liver failure to liver transplantation by the AMC-bioartificial liver. Cell Transplant 2003;12:563-568.
31. Flendrig LM, la Soe JW, Jörning GG, Steenbeek A, Karlsen OT, Bovée WM, et al. In vitro evaluation of a novel bioreactor based on an integral oxygenator and a spirally woundnonwoven polyester matrix for hepatocyte culture as small aggregates. J Hepatol 1997;26:1379-1392.
32. van de Kerkhove MP, Di Florio E, Scuderi V, Mancini A, Belli A, Bracco A, et al. Phase I clinical trial with the AMCbioartificial liver. Int J Artif Organs 2002;25:950-959.
33. Sauer IM, Kardassis D, Zeillinger K, Pascher A, Gruenwald A, Pless G, et al. Clinical extracorporeal hybrid liver support--phase I study with primary porcine liver cells. Xenotransplantation 2003;10:460-469.
34. Sauer IM, Zeilinger K, Pless G, Kardassis D, Theruvath T, Pascher A, et al. Extracorporeal liver support based on primary human liver cells and albumin dialysis--treatment of a patient with primary graft non-function. J Hepatol 2003; 39:649-653.
35. Sauer IM, Zeilinger K, Obermayer N, Pless G, Grünwald A, Pascher A, et al. Primary human liver cells as source for modular extracorporeal liver support--a preliminary report. Int J Artif Organs 2002;25:1001-1005.
36. Morsiani E, Pazzi P, Puviani AC, Brogli M, Valieri L, Gorini P, et al. Early experiences with a porcine hepatocyte-based bioartificial liver in acute hepatic failure patients. Int J Artif Organs 2002;25:192-202.
37. Morsiani E, Brogli M, Galavotti D, Bellini T, Ricci D, Pazzi P, et al. Long-term expression of highly differentiated functions by isolated porcine hepatocytes perfused in a radial-flow bioreactor. Artif Organs 2001;25:740-748.
38. Xue YL, Zhao SF, Luo Y, Li XJ, Duan ZP, Chen XP, et al. TECA hybrid artificial liver support system in treatment of acute liver failure. World J Gastroenterol 2001;7:826-829.
39. Ding YT, Qiu YD, Chen Z, Xu QX, Zhang HY, Tang Q, et al. The development of a new bioartificial liver and its application in 12 acute liver failure patients. World J Gastroenterol 2003;9:829-832.
40. Donato MT, Castell JV, Gómez-Lechón MJ. Characterization of drug metabolizing activities in pig hepatocytes for use in bioartificial liver devices: comparison with other hepatic cellular models. J Hepatol 1999;31:542-549.
41. Cowan PJ, d'Apice AJ. The coagulation barrier in xenotransplantation: incompatibilities and strategies to overcome them. Curr Opin Organ Transplant 2008;13:178-183.
42. Kanai H, Marushima H, Kimura N, Iwaki T, Saito M, Maehashi H, et al. Extracorporeal bioartificial liver using the radial-flow bioreactor in treatment of fatal experimental hepatic encephalopathy. Artif Organs 2007;31:148-151.
43. Enosawa S, Miyashita T, Fujita Y, Suzuki S, Amemiya H, Omasa T, et al. In vivo estimation of bioartificial liver with recombinant HepG2 cells using pigs with ischemic liver failure. Cell Transplant 2001;10:429-433.
44. Enosawa S, Miyashita T, Tanaka H, Li X, Suzuki S, Amemiya H, et al. Prolongation of survival of pigs with ischemic liver failure by treatment with a bioartificial liver using glutamine synthetase transfected recombinant HepG2. Transplant Proc 2001;33:1945-1947.
45. Wang N, Tsuruoka S, Yamamoto H, Enosawa S, Omasa T, Sata N, et al. The bioreactor with CYP3A4- and glutamine synthetase-introduced HepG2 cells: treatment of hepatic failure dog with diazepam overdosage. Artif Organs 2005;29: 681-684.
46. Enosawa S, Miyashita T, Saito T, Omasa T, Matsumura T. The significant improvement of survival times and pathological parameters by bioartificial liver with recombinant HepG2 in porcine liver failure model. Cell Transplant 2006;15:873-880.
47. Nyberg SL, Remmel RP, Mann HJ, Peshwa MV, Hu WS, Cerra FB. Primary hepatocytes outperform Hep G2 cells as the source of biotransformation functions in a bioartificial liver. Ann Surg 1994;220:59-67.
48. Mavri-Damelin D, Damelin LH, Eaton S, Rees M, Selden C, Hodgson HJ. Cells for bioartificial liver devices: the human hepatoma-derived cell line C3A produces urea but does not detoxify ammonia. Biotechnol Bioeng 2008;99:644-651.
49. Werner A, Duvar S, Müthing J, Büntemeyer H, Lünsdorf H, Strauss M, et al. Cultivation of immortalized human hepatocytes HepZ on macroporous CultiSpher G microcarriers. Biotechnol Bioeng 2000;68:59-70.
50. Werner A, Duvar S, Müthing J, Büntemeyer H, Kahmann U, Lünsdorf H, et al. Cultivation and characterization of a new immortalized human hepatocyte cell line, HepZ, for use in an artificial liver support system. Ann N Y Acad Sci 1999; 875:364-368.
51. Kobayashi N, Miyazaki M, Fukaya K, Inoue Y, Sakaguchi M, Noguchi H, et al. Establishment of a highly differentiated immortalized human hepatocyte cell line as a source of hepatic function in the bioartificial liver. Transplant Proc 2000;32:237-241.
52. Kobayashi N, Noguchi H, Watanabe T, Matsumura T, Totsugawa T, Fujiwara T, et al. A tightly regulated immortalized human fetal hepatocyte cell line to develop a bioartificial liver. Transplant Proc 2001;33:1948-1949.
53. Deurholt T, van Til NP, Chhatta AA, ten Bloemendaal L, Schwartlander R, Payne C, et al. Novel immortalized human fetal liver cell line, cBAL111, has the potential to differentiate into functional hepatocytes. BMC Biotechnol 2009;9:89.
54. Poyck PP, van Wijk AC, van der Hoeven TV, de Waart DR, Chamuleau RA, van Gulik TM, et al. Evaluation of a new immortalized human fetal liver cell line (cBAL111) for application in bioartificial liver. J Hepatol 2008;48:266-275.
55. Kobayashi N, Westerman KA, Tanaka N, Fox IJ, Leboulch P. A reversibly immortalized human hepatocyte cell line as a source of hepatocyte-based biological support. Addict Biol 2001;6:293-300.
56. Kobayashi N. Life support of artificial liver: development of a bioartificial liver to treat liver failure. J Hepatobiliary Pancreat Surg 2009;16:113-117.
57. Kobayashi N, Fujiwara T, Westerman KA, Inoue Y, Sakaguchi M, Noguchi H, et al. Prevention of acute liver failure in rats with reversibly immortalized human hepatocytes. Science 2000;287:1258-1262.
58. Totsugawa T, Yong C, Rivas-Carrillo JD, Soto-Gutierrez A, Navarro-Alvarez N, Noguchi H, et al. Survival of liver failure pigs by transplantation of reversibly immortalized human hepatocytes with Tamoxifen-mediated self-recombination. J Hepatol 2007;47:74-82.
59. Dalgetty DM, Medine CN, Iredale JP, Hay DC. Progress and future challenges in stem cell-derived liver technologies. Am J Physiol Gastrointest Liver Physiol 2009;297:G241-G248.
60. Dan YY, Yeoh GC. Liver stem cells: a scientific and clinical perspective. J Gastroenterol Hepatol 2008;23:687-698.
61. Chamuleau RA, Deurholt T, Hoekstra R. Which are the right cells to be used in a bioartificial liver? Metab Brain Dis 2005; 20:327-335.
62. Ding YT, Shi XL. Bioartificial liver devices: Perspectives on the state of the art. Front Med 2011;5:15-19.
63. Davies B, Morris T. Physiological parameters in laboratory animals and humans. Pharm Res 1993;10:1093-1095.
64. Hay PD, Veitch AR, Smith MD, Cousins RB, Gaylor JD. Oxygen transfer in a diffusion-limited hollow fiber bioartificial liver. Artif Organs 2000;24:278-288.
65. Hay PD, Veitch AR, Gaylor JD. Oxygen transfer in a convection-enhanced hollow fiber bioartificial liver. Artif Organs 2001;25:119-130.
66. Chen G, Palmer AF. Perfluorocarbon facilitated O(2) transport in a hepatic hollow fiber bioreactor. Biotechnol Prog 2009;25:1317-1321.
67. Chen G, Palmer AF. Mixtures of hemoglobin-based oxygen carriers and perfluorocarbons exhibit a synergistic effect in oxygenating hepatic hollow fiber bioreactors. Biotechnol Bioeng 2010;105:534-542.
68. Chen G, Palmer AF. Hemoglobin-based oxygen carrier and convection enhanced oxygen transport in a hollow fiber bioreactor. Biotechnol Bioeng 2009;102:1603-1612.
69. Remy B, Deby-Dupont G, Lamy M. Red blood cell substitutes: fluorocarbon emulsions and haemoglobin solutions. Br Med Bull 1999;55:277-298.
70. Seghatchian J, de Sousa G. An overview of unresolved inherent problems associated with red cell transfusion and potential use of artificial oxygen carriers and ECO-RBC: current status/future trends. Transfus Apher Sci 2007;37:251-259.
71. Natanson C, Kern SJ, Lurie P, Banks SM, Wolfe SM. Cell-free hemoglobin-based blood substitutes and risk of myocardial infarction and death: a meta-analysis. JAMA 2008;299:2304-2312.